Straumann (OTCMKTS:SAUHF) and Item 9 Labs (OTC:INLB) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, analyst recommendations, earnings and risk.
Earnings & Valuation
This table compares Straumann and Item 9 Labs’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Straumann||$1.52 billion||18.88||$97.36 million||N/A||N/A|
|Item 9 Labs||$8.12 million||11.07||-$12.27 million||N/A||N/A|
Insider and Institutional Ownership
0.1% of Straumann shares are held by institutional investors. 19.8% of Item 9 Labs shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
This is a summary of recent ratings and target prices for Straumann and Item 9 Labs, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Item 9 Labs||0||0||1||0||3.00|
Item 9 Labs has a consensus price target of $4.00, suggesting a potential upside of 316.67%. Given Item 9 Labs’ higher possible upside, analysts clearly believe Item 9 Labs is more favorable than Straumann.
Risk and Volatility
Straumann has a beta of 1.04, meaning that its stock price is 4% more volatile than the S&P 500. Comparatively, Item 9 Labs has a beta of 0.99, meaning that its stock price is 1% less volatile than the S&P 500.
This table compares Straumann and Item 9 Labs’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Item 9 Labs||-49.00%||-12.20%||-10.29%|
Straumann beats Item 9 Labs on 8 of the 11 factors compared between the two stocks.
Straumann Holding AG engages in the provision of implant, restorative, and regenerative dentistry solutions to dental professionals and laboratories. It operates through the following segments: Sales Europe, Sales Distributor & Emerging Markets EMEA, Sales NAM, Sales APAC, Sales LATAM, and Operations. The Sales Europe segment comprises of the Group’s premium and Instradent distribution business. The Sales Distributor & Emerging Markets EMEA segment consists of premium and Instradent distribution businesses in Russia, as well as the premium business with European, African, and Middle Eastern distributors. The Sales NAM segment includes ClearCorrect’s clear-aligner business and its associated development and production activities. The Sales APAC involves in the distribution business of Anthogyr implants and prosthetic components in China and the Equinox implants in India. The Sales LATAM segment includes distribution and Instradent businesses in Middle and South America, and Latin America. The Operations segment manufactures plants, implants, and biomaterials. The company was founded by Reinhard Straumann in 1954 and is headquartered in Basel, Switzerland.
About Item 9 Labs
Item 9 Labs Corp. focused on development, manufacturing and distribution of nasal breathing and intra-nasal delivery devices. The Company’s Air Allergy is a discreet personal filter which protects from irritating airborne allergens. Air Sleep/Snore provides drug-free relief for congestion and snoring caused by nasal breathing difficulties. Item 9 Labs Corp., formerly known as Airware Labs Corp, is headquartered in Southern Arizona, United States.
Receive News & Ratings for Straumann Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Straumann and related companies with MarketBeat.com's FREE daily email newsletter.